PIN17 Public Health And Economic Impact of A Quadrivalent Influenza Vaccine In Comparison to The Trivalent Influenza Vaccine In Brazil Over The Period Of 2010 – 2013  by Bricks, L et al.
A578  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
associated with high therapeutic efficiency, and are expected to maximize the 
years of life of the Portuguese genotype-1 HCV patients.
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ModelINg of UsINg RIlPIvIRINe/ TeNofovIR/ eMTRIcITabINe IN 
TReaTMeNT of Naïve HIv-1 INfecTed PaTIeNs
Yagudina R, Kulikov A, Babiy VV
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To estimate long-term clinical outcomes of using rilpivirine/tenofo-
vir/emtricitabine (single tablet regimen) in treatment of naïve patients with HIV-1 
RNA< 100 000 copies/ml in the Russian Federation. MethOds: The mathematical 
model was developed in Microsoft Office 2013. The time horizon was 5 years. The 
model included two submodels: Markov’s model and tree-decision model. The fol-
lowing outcome measures were used in present study: Number of deaths, Years of 
life lost, Number of hospitalizations. All calculations were based on results of pub-
lished clinical, epidemiological and social researches. Data for patients with HIV was 
obtained from prior epidemiological studies that had been provided in the Russian 
Federation. Results: The number of deaths on rilpivirine/tenofovir/emtricitabine 
scheme (single tablet regimen) was 12% and 15% less, the number of YLL was 9% 
and 12% less and Number of hospitalizations was 19,91% and 19,88% less than on 
the schemes efavirenz + tenofovir/ emtricitabin (multi-pill regimen) and lopinavir 
+ tenofovir/ emtricitabin (multi-pill regimen), respectively. cOnclusiOns: Results 
obtained with present model showed that treatment naïve patients with HIV-1 
RNA< 100 000 copies/ml using rilpivirine/tenofovir/emtricitabine scheme (single 
tablet regimen) can be associated with better long-term outcomes compared to 
alternative multi-pill schemes.
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INdIRecT coMPaRIsoN foR e/c/f/Taf IN TReaTMeNT Naïve HIv PaTIeNTs
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Objectives: E/C/F/TAF is the combination of Elvitegravir/Cobicistat/Emtricitabine 
with Tenofovir Alafenamide, a new prodrug of tenofovir with a better biodisponibil-
ity and safety profile than Tenofovir Disoproxil Fumarate (TDF) . We used adjusted 
indirect comparison to estimate the relative efficacy of E/C/F/TAF versus HAART 
based on raltegravir (RAL) or dolutegravir (DTG) in treatment-naïve HIV-1 infected 
patients that was not directly studied in head-to-head randomized controlled tri-
als. MethOds: A systematic review of published literature was conducted to iden-
tify phase 3 randomized controlled clinical trials (up to February 2015) including 
at least one third agent of interest. Network adjusted indirect comparison was 
used to evaluate week 48 relative effectiveness (HIV-RNA suppression to 50 copies/
mL) after checking for homogeneity and absence of interaction between baseline 
characteristics and efficacy. Analyses based on secondary networks were performed 
to assess validity. A ten percent margin was used for non-inferiority. Results: 
Twelve studies were included in the network. Baseline patient’s characteristics were 
slightly different between studies published before and after 2011 due to changes in 
2011 in treatment initiation guidelines. No significant interactions were observed 
in the studies between baseline characteristics and week 48 virologic suppression. 
E/C/F/TAF was associated with a non-significant different rate for week 48 virologic 
suppression compared to DTG + ABC/3TC or RAL + TDF/FTC (Relative Risk = 0.98 
(0.89 - 1.07) and 1.01 (0.92 - 1.12) respectively). Using secondary networks yielded 
similar results. cOnclusiOns: This indirect comparison suggests that with ten 
percent non-inferiority margin E/C/F/TAF has a similar efficacy then DTG or RAL 
based HAART.
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Objectives: Trivalent influenza vaccine (TIV), which contains two strains of 
influenza A and one strain of influenza B is recommended by the Brazilian gov-
ernment to prevent influenza. However, co-circulation of two distinct B lineages 
and difficulties in predicting which lineage will predominate in the next season 
led to the development of quadrivalent influenza vaccine (QIV). The aim of the 
study was to estimate the public health (epidemiological) and economic impact 
of the QIV over four influenza seasons (2010 to 2013) in the Brazilian population 
in comparison with TIV. MethOds: A static model published by Reed et al. in 
2012 was adapted to Brazil and stratified by age group. The model retrospectively 
calculated impact using vaccine effectiveness and coverage, illness incidence, 
morbidity, mortality and costs related to influenza from the Public Healthcare 
System and Society perspectives. Vaccine effectiveness by strain and by age in 
the Brazilian population is not available; therefore we used vaccine effectiveness 
from Clements et al., which takes into account some B-lineage cross-protection. 
Epidemiological and resource use data were obtained from the Brazilian pub-
lic system database (DATASUS) and regional studies. Costs were expressed in 
2015 Brazilian Real, vaccine cost was not considered and exchange rate used was 
$1.00USD= 3.14BRL. Results: The use of QIV vaccination instead of TIV in the 
years from 2010 to 2013 would have avoided a total of additional 654,018 cases, 
323,336 consultations, 7,536 hospitalizations and 1,122 deaths due to influenza. In 
2013, year with high B circulation and high mismatch, considering a public payer 
and societal perspective, respectively, QIV vaccination could have avoided addi-
tional influenza costs estimated at BRL 11 million and 62 million (USD 3.5 million 
and 20 million). cOnclusiOns: Vaccination with QIV for the Brazilian population 
is expected to result in public health benefit and less resource use when compared 
to TIV.
patients. MethOds: A SLR identified randomised controlled trials (RCTs) of TDF/
FTC or ABC/3TC plus third agents grouped by class (protease inhibitors [PI], non-
nucleoside reverse transcriptase inhibitors [NNRTI] and integrase strand transfer 
inhibitors [INSTI]) in HIV-1 infection. MEDLINE, EMBASE and the Cochrane Library 
were searched in March 2014. Bayesian NMAs of RCTs in were run for virologic 
response (VR) and all-cause discontinuation at Week 48 (Wk48) and 96 (Wk96). 
Inconsistency and the effect of baseline characteristics were also assessed using 
unrelated mean-effects models and meta-regression, respectively. Results: Of 
1,093 citations retrieved, 243 citations were included in the SLR, reporting 18 RCTs 
that informed at least one network. In the NMA, fixed-effect models represented 
a better fit for VR data, whereas random-effects models fitted the all-cause dis-
continuation data best. With NNRTIs, TDF/FTC was associated with significantly 
higher odds of VR than ABC/3TC at Wk48 (OR 1.32 [95%CrI 1.05, 1.65]) and Wk96 
(OR 1.29 [95%CrI 1.03, 1.61]). With INSTIs, TDF/FTC had a significantly higher odds 
of VR at Wk96 compared with ABC/3TC (OR 1.46 [95%CrI 1.04, 2.04]). No statistically 
significant differences in VR were found between the backbones with PIs. No sta-
tistically significant differences in all-cause discontinuation at Wk48 or Wk96 were 
observed between the backbones with any class of third agent. Networks showed 
little inconsistency, and baseline characteristics did not have any significant effect 
on results. cOnclusiOns: TDF/FTC was associated with statistically significant 
VR benefits compared with ABC/3TC with NNRTIs at both Wk48 and Wk96 and 
with INSTIs at Wk96, and no statistically significant effect was seen with respect 
to all-cause discontinuation.
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Objectives: There is no consistent evidence of clinical efficacy of IgM-enriched 
intravenous immunoglobulin (IgM) for reducing mortality in adults, newborns and 
older children with bacterial infections and sepsis. The aim of the study was to 
update evidence by considering recent clinical trials and analyzing age popula-
tions and comparators separately. MethOds: We searched publications in PubMed 
and the Cochrane Library in December 2014. All-cause mortality was analyzed, 
and systematic review using meta-analysis and indirect comparison was carried 
out. Results: Five meta-analyses and 18 RCTs were considered, including 12 trials 
studied the effect of IgM in adults, 5 in newborns, and one in children 1-24 months 
old. All interventions were applied with basic therapy (BT). No difference between 
IgM and albumin was found for adults. However we found significant efficacy of 
IgM in adults when compared with all comparators, RR 0.69 [0.56; 0.84], and BT, 
RR 0.52 [0.39; 0.69]. In newborns mortality is lower in IgM than in all comparators 
groups, RR 0.47 [0.29; 0.76], and in BT with or without placebo, RR 0.50 [0.30; 0.84]. 
Children under 24 months receiving IgM also had lower mortality than in all com-
parators group, RR 0.48 [0.34; 0.68]. Indirect comparison of IgM and IgG in adults 
showed no differences, in newborns the difference is in favor of IgM, RR 0.47 [0.29; 
0.77]. cOnclusiOns: IgM is effective in reducing all-cause mortality in adults with 
bacterial infection or sepsis in comparison with BT; also in newborns in comparison 
with any comparators (BT with or without placebo, albumin, IgG), in children under 
24 months in comparison to BT with or without albumin. Further head-to-head 
clinical trials are needed to enhance evidence.
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Objectives: Chronic hepatitis C (CHC) is a major public health problem affecting 
1.5% of the Portuguese population and reducing life expectancy by 20 years. The 
most recent international guidelines recommend the utilization of sofosbuvir 
(SOF) as backbone for the treatment of CHC patients. The association of ledipasvir 
(LDV) to SOF enhances SOF efficacy and safety, especially in patients infected with 
genotype-1 hepatitis C virus. Additionally, it allows the treatment of CHC patients 
without using pegylated interferon-α (PegIFN) and ribavirin (RBV). The objective of 
this study was to estimate LDV/SOF’s contribution to the Portuguese public health 
by exhausting CHC therapeutic efficiency. MethOds: Therapeutic efficiency was 
defined as maximum capacity to benefit from treatment in terms of life years 
(LY) relative to the general population’s life expectancy. The natural history of 
CHC and treatment implication was modelled with a Markov model allowing for 
long-term assessment in terms of HCV fibrosis progression. Comparators used 
were SOF+PegIFN+RBV, SOF+RBV, boceprevir+PegIFN+RBV and PegIFN+RBV, taking 
into consideration the therapeutic options currently financed by the Portuguese 
National Health System, the recommendation of SOF as the standard of care and 
the coincidence between therapeutic indications. Results: In HCV genotype-1 
non-cirrhotic patients, LDV/SOF treatment is estimated to result in 0.21 LY, 1.5 LY 
or 1.44-2.90 LY gained in comparison to SOF+PegIFN+RBV, SOF+RBV or the options 
financed by the Portuguese NHS, respectively; for patients with cirrhosis, these 
values are 1.20 LY, 4.08 LY or 1.33-4.67 LY, respectively. In patients infected with 
HCV genotype-1, LDV/SOF is expected to enhance life expectancy, with therapeutic 
efficiency ranging from 86.2% to 98.4%. cOnclusiOns: LDV/SOF regimens are 
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Fifty one percent severely dehydrated with Systolic BP ranged 0.0–160.0mmHg, 
median 90.0mmHg. Diastolic BP ranged 0.0-110.0 mmHg, median 60.0mmHg. Total 
fluids given ranged 0.0–13.9 L, median 5.2 L. Only 1.4% had fluid output monitored. 
Lacking health insurance (POR= 2.52, ci0.48-13.25), being referred (POR= 0.05, ci0.01-
0.21), male (POR= 0.82, ci0.32-2.16), single (POR= 0.80, ci0.26-2.46) were associated 
with late hospital presentation cOnclusiOns: Instituting routine cholera death 
audits in Ghana is crucial to reducing case fatality as late presentation, inadequacy 
of assessment, rehydration, monitoring and lack of Health Insurance were main 
prevalent factors among deaths in the outbreak.
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age RelaTed coNsUlTaTIoN RaTes of clINIcally-dIagNosed INflUeNza 
aNd acUTe ResPIRaToRy IllNesses obseRved THRoUgH a NeTwoRk of gP 
PRacTIces acRoss eNglaNd
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Objectives: Influenza infection can be recorded under number of respiratory diag-
noses when patients visit a GP. In addition, the incidence of influenza and respiratory 
infections are known to be highest in younger and elderly age groups. Our objective 
was to describe the consultation rates for eight respiratory diagnoses across four 
influenza seasons as observed through GP consultations in England. MethOds: 
Data were obtained on 775,000 respiratory related GP consultations, across four 
influenza seasons (2010-2014) from the Clinical Practitioners Research Datalink. 
Eligible patients were registered and had 12 months history with a practice at the 
start of the season. An influenza season was defined as 1 September through to 
13 April of the following year. Practice-level consultation rates for each outcome 
were determined by age (seven groups were defined) and season. A Poisson mixed 
effect model was fitted to analyse age effect with inter-practice and inter-season as 
random effects. 18 to 65 age group was the reference population. Results: Across 
all outcomes, consultation rates for influenza or respiratory illness were highest 
amongst young children, with highest rates observed for the 0 to < 2 age group, fol-
lowed by the 2 to < 4 age group. Focussing on individual diagnoses recorded during 
GP consultations, younger children were particularly at risk for upper respiratory 
tract infection and otitis media. Patients over 65 were found to be more at risk for 
pneumonia and lower respiratory tract infection. Inter-practice variation in diag-
noses rates was dominating inter-season variations for most influenza-related 
diagnoses. Biggest seasonal impact was on consultations for influenza-like-illness, 
which were particularly high during the 2010-2011 season, likely due to the H1N1 
epidemic. cOnclusiOns: Our findings confirmed that children and the over 65 
population are most at risk of influenza and respiratory illness, and that incidence 
can reliably be evaluated through analysis of GP consultation rates.
INfecTIoN – cost studies
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HealTH ecoNoMIc IMPacT of 13-valeNT PNeUMococcal coNjUgaTe 
vaccINe IN fINNIsH HoMe caRe cUsToMeRs ≥ 50 yeaRs wITH UNdeRlyINg 
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Objectives: Hospital-treated pneumonias (HTP) are associated with substantial 
individual and societal burden in adults (≥ 50 years) and elderly. Moreover, adults 
e.g. with vascular, metabolic or respiratory diseases have a 3-6 times higher risk 
of HTP when compared with their healthy controls. Persons at risk are likely to 
benefit most from pneumococcal vaccinations. The 13-valent pneumococcal con-
jugate vaccine (PCV13) has showed to prevent community-acquired pneumonia and 
invasive pneumococcal disease in adults. The objective of this study was to estimate 
the expected 5-year health economic impact of targeted PCV13 compared with no 
vaccination in Finnish home care customers. MethOds: A budget impact model 
was developed to predict the impact of PCV13 vaccination in terms of costs and 
HTP events avoided at the national and municipal level. A dynamic-cohort Markov 
modelling approach and a time horizon of 5 years was used. The baseline number 
of home care customers and HTP events were gathered from Finnish national regis-
tries. The efficacy of PCV13 was estimated based on CAPITA trial. Only direct costs in 
2014 value were considered in the analysis. Results: All 105,572 Finnish home care 
customers are considered to be at moderate or high risk for HTP because of under-
lying chronic medical conditions. Vaccination of these people with PCV13 could 
provide an undiscounted net budget savings of about € 49.2 million compared with 
the current no-vaccination situation over the next 5 years. Among the risk groups 
considered, the largest absolute undiscounted net savings (€ 22.3 million) could be 
obtained by vaccinating people with heart disease, due to its high prevalence in the 
target population. cOnclusiOns: In Finland, the direct immunization of home 
care customers with PCV13, is estimated to lead to substantial cost savings in the 
following 5 years after vaccination.
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Objectives: Chronic HCV is a leading cause of hospitalization and death in popu-
lations coinfected with HIV in Italy. Sofosbuvir (SOF) is a pan-genotypic drug, which 
can be used alone or combined with other agents (e.g.Simeprevir,Daclatasvir, 
Ledipasvir) as oral treatment for HCV, with different price levels. We performed 
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Objectives: To estimate prevalence of HCV, using data from routine practice in 
Italy MethOds: An observational retrospective cohort based on administrative 
databases (containing data from pharmacy registries, hospital discharges, outpa-
tient specialist services and laboratory tests) from a sample of six Italian LHUs was 
performed. The date of the first record related to HCV (i.e., positive HCV testing 
or medications for HCV) during the study period (July 1st, 2009 - June 31st, 2014) 
was considered as a proxy of diagnosis, and used as the index date. Patients with 
data available for at least 6 months prior to index date were followed up from the 
index date until the first of the end of the study period, date of death, or exiting the 
database Results: Overall, 228,157 health-assisted individuals living in the first 
analysed LHU (Central Italy) were considered as the starting population in the study; 
amongst them, 0.4% patients with HCV were enrolled, 56% male, age 58±16 years. 
The most prevalent genotypes were 1 (51±2%), 2 (24±2%), 3 (19±2%) and 4 (5±1%); 
other genotypes had a rate lower than 5%. In terms of co-infections, 6% patients 
were affected by HIV, 3% by HBV, 2% HCV+HBV+HIV, 26% had cirrhosis and 4% HCC. 
The majority of patients (76%) did not receive an antiviral treatment; compared to 
treated patients, they were more frequently aged > 65 years (44% compared to 14% 
in treated patients), females (46%, vs 40%), under ongoing substance/alcohol abuse 
(7% vs 4%). Moreover, 30% of untreated patients had cirrhosis and 5% HCC. Results 
from other LHUs will be available at ISPOR-EU cOnclusiOns: This observational 
study showed that 70% of enrolled HCV patients has genotype 1 and 3, and only 
a small proportion of patients with HCV received antiviral therapy. Future analy-
ses should investigate relationships between patients’ characteristics, therapeutic 
choices and outcomes
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Objectives: Rotavirus gastroenteritis (RVGE) is the leading cause of severe diarrhea 
in children under 5 years of age. Two rotavirus vaccines are licensed to prevent these 
infections. More than hundred economic evaluations have been published on rota-
virus vaccination since 2006 and their results largely vary. An update of a literature 
view was conducted aiming to assess whether differences in the epidemiologi-
cal data used in European evaluations could explain the differences in the results 
obtained. MethOds: A literature review was conducted to retrieve articles reporting 
the cost-effectiveness of rotavirus vaccination in Europe based on criteria used in 
a previously published review (limited to 2001-2011 studies, this update extended 
the search to May 2015), focusing on epidemiological data. The following annual 
incidence RVGE-related data were extracted from the retrieved articles and grouped 
by countries: community-acquired hospitalisation (CAH), emergency department 
(ED) visits, outpatient visits (including general practitioner or paediatrician) and 
RVGE events (including no medical visits). Variations within countries were also 
calculated as the ratio between the maximum and minimum value. Results: 32 
publications (24 manuscripts and 8 conference abstracts) from 13 European coun-
tries were retrieved. The European average (minimum and maximum reported 
value) annual rates were CAH 0.57% (0.09% Portugal; 1.43% Albania), ED visits 1.13% 
(0.22% Portugal; 2.40% France), outpatient visits 3.11% (0.56% Netherlands; 7.17% 
Romania) and RVGE events 9.05% (5.63% Germany; 20.01% Spain). For the countries 
with multiple publications, rates of CAH and outpatient visits showed large variation 
(CAH: France 2.82; outpatient: Ireland 5.78). RVGE rates were generally consistent 
except for United Kingdom (1.93) and Germany (2.50). For ED visit rates the largest 
variability was observed in France (3.16). cOnclusiOns: The RGVE disease bur-
den used as input in economic evaluation varies among the studies in the same 
country and across Europe. This may explain the difference in the cost-effective 
results reported.
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Objectives: Ghana has documented recurrent Cholera outbreaks (Davies-Teye, 
2014); the worst ever in 2014 had high case, death incidence and yet does not rou-
tinely audit these deaths. Auditing the deaths would improve healthcare quality 
delivered to clients This study aimed at developing standardized Cholera Death 
audit tool, describe the deaths and identify prevalent factors that contributed to 
deaths. MethOds: Standardized cholera death audit tool was developed. Census 
of cholera deaths from June – December 2014 in Greater Accra Region made. Medical 
records, surveillance data of deaths from treatment centers reviewed with the devel-
oped audit tool. Data abstracted included socio-demographic, clinical, patient moni-
toring. Data managed in Epi info7. Descriptive, bivariate analysis made and Prevalent 
Odds Ratio (95% Confidence Interval) determined to identify prevalent factors asso-
ciated with deaths. Results: The region documented 20,199 (Attack rate 432 per 
100,000 populations) cholera cases with 121 deaths (CFR 0.60%). La Nkwantanang-
Madina and Ladade Kotopon were most affected with Attack rates above 600 per 
100,000 populations. Ada East, Ashaiman and LEKMA had case fatalities above 0.9%. 
Ages ranged 1–82 years, mean 41.0 ±17, median 39.0, mode 24.0 years. Males consti-
tuted 65.7% and 90.9% did not have health insurance. Duration of home stay ranged 
0-5days. Nineteen percent were dead on arrival and 20.2% within 4hours of arrival. 
